IO Biotech appoints Amy Sullivan as CFO effective Oct 15, 2022

IO Biotech, Inc.

Amy Sullivan, 53, appointed CFO and Principal Financial Officer, effective October 15, 2022.
Annual base salary of $425,000 and target bonus of 45% of base salary.
Granted option for 288,152 shares; vests 25% at 1 year, then monthly over 3 years.
Ms. Sullivan previously served as CFO at TABA and chief strategy officer at Kiadis Pharma, leading its sale to Sanofi.
She brings 25+ years of life sciences finance and corporate strategy experience.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Amy Sullivan

Chief Financial Officer

IOBTQ · IO Biotech, Inc.

Effective: 2022-10-15
Filed: October 13, 2022, 7:59 PM ET

On October 13, 2022, IO Biotech, Inc. (the “Company”) appointed Amy Sullivan, 53, as the Company’s Chief Financial Officer, effective as of October 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Sullivan was appointed as Chief Financial Officer at IO Biotech, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On October 13, 2022, IO Biotech, Inc. (the “Company”) appointed Amy Sullivan, 53, as the Company’s Chief Financial Officer, effective as of October 15, 2022.

View on SEC.gov

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-262152

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.